Investigators from the QUAZAR trial report that treatment with oral azacytidine (CC-486), significantly improves survival in older patients, over age of 55, with AML acute myeloid leukemia (AML). […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.
